Top

Clinical and Experimental Nephrology

Published in:

01-02-2019 | Original article

Breath analysis as promising indicator of hemodialysis efficiency

Authors: B. Grabowska-Polanowska, P. Miarka, M. Skowron, G. Chmiel, A. Pietrzycka, I. Śliwka

Published in: Clinical and Experimental Nephrology | Issue 2/2019

Abstract

Background

The measurement of trimethylamine and isoprene in exhaled breath collected from dialysed patients indicates the changes in concentration of both compounds during dialysis. The aim of the presented study was to confirm diagnostic usefulness of TMA and isoprene detected in breath, as potential biomarkers of hemodialysis efficiency.

Methods

The samples of exhaled breath were collected from 22 dialyzed patients (9 women, 13 men) before and after hemodialysis (HD). All analyses were carried out using a gas chromatograph equipped with a mass spectrometer. Thermal desorption was used as breath sample enrichment method.

Results

Chromatographic analysis of breath samples indicated statistically significant differences in trimethylamine (TMA) and 2-methyl-1,3-butadiene (isoprene) concentrations in patients’ breath collected before and after HD. TMA concentrations measured in breath samples, before dialysis, ranged from 0.024 to 0.461 nmol/L. After dialysis, the values of detected TMA were lower versus output values and ranged from 0.008 to 0.050 nmol/L. Isoprene concentrations before dialysis were present in the range from 0.236 to 9.718 nmol/L, after dialysis in the range from 0.478 to 26.182 nmol/L. Additionally, the dependences of TMA and isoprene concentrations, detected in breath with renal efficiency parameters detected in blood, were studied. The relationships between TMA and urea (r = 0.67; p < 0.00001) and creatinine (r = 0.61; p = 0.00002) were checked. In case of isoprene considerably higher concentrations were observed after dialysis, but no statistically significant correlation of isoprene with blood parameters was noticed.

Conclusion

The observed decrease of TMA concentrations during dialysis could be useful as a measure of dialysis efficiency. The explanation of isoprene increase in breath during dialysis requires further investigation.

Sułowicz W. Practical aspects of dialysis quality assessment. Forum Nefrologiczne. 2010;3(3):185–92.

Charra B, Calemard E, Ruffet M, Chazot C, Terrat J-C, Vanel T, et al. Survival as an index of adequacy of dialysis. Kidney Int. 1992;41:1286–91.CrossRefPubMed

Locatelli F. Dose of dialysis, convection and haemodialysis patients outcome—what the HEMO study doesn’t tell us: the European viewpoint. Nephrol Dial Transplant. 2003;18:1061–5.CrossRefPubMed

Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010–9.CrossRef

Sułowicz W. Practical aspects of dialysis quality assessment. Forum Nefrologiczne. 2010;3:185–92.

Basile C, Casino F, Lopez T. Percent reduction in blood urea concentration duringdialysis estimates Kt/V in a simple and accurate way. Am J Kidney Dis. 1990;15(1):40–5.CrossRefPubMed

Kessler M, Canaud B, Pedrini LA. European best practice guidelines for hemodialysis (part 1). Section II. Hemodialysis adequacy. Nephrol Dial Transplant. 2002;17(Suppl 7):17–31.

Simenhoff ML, Burke JF, Suakkonen JJ. Biochemical profile or uremic breath. N Engl J Med. 1977;297:132–5.CrossRefPubMed

Bain MA, Faullb R, Fornasinic G, Milnea RW, Schumannd R, Evans AM. Quantifying trimethylamine and trimethylamine-N-oxide in human plasma: interference from endogenous quaternary ammonium compounds. Anal Biochem. 2004;334:403–5.CrossRefPubMed

10.

Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients haemodialysis. Nephrol Dial Transplant. 2006;21:1300–4.CrossRefPubMed

11.

Davies SJ, Spanel P, Smith D. Breath analysis ammonia, volatile organic compounds and deuterated watervapour in chronic kidney disease and during dialysis. Bioanalysis. 2014;6(6):843–57.CrossRefPubMed

12.

Weiner ID, Mitch WE, Sands JM. Urea and ammonia metabolism and the controlof renal nitrogen excretion. Clin J Am Soc Nephrol 2014:13.

13.

Endre ZH, Pickering JW, Storer MK, Hu W-P, Moorhead KT, Allardyce R, et al. Breath ammonia and trimethylamine allow real-time monitoring of haemodialysis efficacy. Physiol Meas. 2011;32(1):115–30.CrossRefPubMed

14.

Lirk P, Bodrogi F, Raifer H, Greiner K, Ulmer H, Rieder J. Elective haemodialysis increases exhaled isoprene. Nephrol Dial Transplant. 2003;18:937–41.CrossRefPubMed

15.

Capodicasa E, Trovarelli G, Medio GED, Pelli MA, Lippi G, Verdura C, et al. Volatile alkanes and increased concentrations of isoprene in exhaled air during hemodialysis. Nephron. 1999;82:331–7.CrossRefPubMed

16.

Davies S, Španel P, Smith D. A new “online” method to measure increased exhaled isoprene in end-stage renal failure. Nephrol Dial Transplant. 2001;16(4):836–9.CrossRefPubMed

17.

Lowis S, Eastwood MA, Brydon WG. The influence of creatinine, lecithin and choline feeding on aliphatic amine production and excretion in the rat. Br J Nutr. 1985;54:43–51.CrossRefPubMed

18.

Zeisel SH, daCosta KA. Increase in human exposure to methylamine precursors of N-nitrosamines after eating fish. Cancer Res. 1986;46(12 Pt 1):6136–8.PubMed

19.

Zhang AQ, Mitchell S, Smith R. Fish odour syndrome: verification of carrier detection test. J Inherit Metab Dis. 1995;18:669–74.CrossRefPubMed

20.

Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–70.CrossRef

21.

Rydzewska-Rososłowska A, Kakareko K, Rosołowski M, Hryszko T, Brzósko S, Myśliwiec M, et al. Microbiom and the kidney. Post N Med. 2016;XXIX(9):659–63.

22.

Manolis A. The diagnostic potential of breath analysis. Clin Chem. 1983;29(1):5–15.PubMed

23.

Deneris ES, Stein RA, Mead JF. In vitro biosynthesis of isoprene from mevalonate utilizing a rat liver cytosolic fraction. Biochem Biophys Res Commun. 1984;123:691–6.CrossRefPubMed

24.

Thomas K, Prazeller P, Mayr D, Jordan A, Rieder J, Fall R, et al. Human breath isoprene and its relation to blood cholesterol levels: new measurements and modeling. J Appl Physiol. 2001;91:762–70.CrossRef

25.

Stone BG, Thiel DHV, Besse TJ, Duane WC, Evans CD, DeMaster EG. Effect of regulating cholesterol biosynthesis on breath isoprene excretion in men. Lipids. 1993;28:705–8.CrossRefPubMed

26.

Salermo-Kenedy R, Cashman KD. Potentil applications of breath isopene as a biomarker in modern medicine: a concose overview. Wien Klin Wochenschr. 2005;117(5–6):180–6.CrossRef

27.

Turner C, Smith PSpanel. D. A longitudinal study of breath isoprene in healthy volunteers using selected ion flow tube mass sectrometry (SIFT-MS). Physiol Meas. 2006;27:13–22.CrossRefPubMed

28.

Kushch I, Arendacka B, Stolc S, Mochalski P, Filipiak W, Schwarz K, et al. Breath isoprene—aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med. 2008;46(7):1011–8.CrossRefPubMed

29.

King JKH, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, Teschl S, Hinterhuber H, Amann A. Physiological modeling of isoprene dynamics in exhaled breath. J Theor Biol. 2010;267:626–37.CrossRefPubMed

30.

King J, Koc H, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, et al. Physiological modeling of isoprene dynamics in exhaled breath. J Theor Biol. 2010;267:626–37.CrossRefPubMed

31.

Wzorek B, Mochalski P, Śliwka I, Amann A. Application of GC-MS with a SPME and thermal desorption technique for determination of dimethylamine and trimethylamine in gaseous samples for medical diagnostic purposes. J Breath Res. 2010;4:1–6.CrossRef

32.

Grabowska-Polanowska B, Faber J, Skowron M, Miarka P, Pietrzycka A, Śliwka I, et al. Detection of potential CKD marker in breath using GC/MS coupled with thermal desorption method. J Chromatogr A. 2013;1301:179–89.CrossRefPubMed

33.

King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Teschl G, Miekisch W, Schubert J, Hinterhuber H, Amann A. Isoprene and acetone concentration profiles during exercise on an ergometer. J Breath Res. 2009;3:027006.CrossRefPubMed

34.

Holmar J, Fridolin I, Uhlin F, Fernström A, Lumana M. Proceedings of the Estonian Academy of Sciences, estimation of dialysis patients’ survival through combined approach of small molecule uremic markers. Biomed Eng. 2014;63(3):315–21. https://doi.org/10.3176/proc.2014.3.0.CrossRef

35.

Grabowska-Polanowska B, Skowron M, Miarka P, Pietrzycka A, Śliwka I. The application of chromatographic breath analysis in the search of volatile biomarkers of chronic kidney disease and coexisting type 2 diabetes mellitus. J Chromatogr B. 2017;1060:103–10.CrossRef

36.

Narasimhan LR, Goodman W, Kumar C, Patel N. Correlation of breath ammonia with blood urea nitrogen and creatinine during hemodialysis. PNAS. 2001;98:4617–21.CrossRefPubMed

37.

Capodicasa E, Trovarelli G, Brunori F, Vecchi L, Carobi C, De M et al. Lack of isoprene overproduction during peritoneal dialysis. Perit Dial Int. 2002;22(1):48–52.PubMed

38.

Takayama F, Tsutsui S, Horie M, Shimokata K, Niwa T. Glutathionyl hemoglobin in uremic patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59(Suppl.78):155–8.CrossRef

39.

Scoppola A, de Paolis P, Menzinger G, Lala A, Glulio SD. Plasma mevalonate concentrations in uremic patients. Kidney Int. 1997;51:908–12.CrossRefPubMed

Title: Breath analysis as promising indicator of hemodialysis efficiency
Authors: B. Grabowska-Polanowska
P. Miarka
M. Skowron
G. Chmiel
A. Pietrzycka
I. Śliwka
Publication date: 01-02-2019
Publisher: Springer Singapore
Published in: Clinical and Experimental Nephrology / Issue 2/2019
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-018-1625-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Breath analysis as promising indicator of hemodialysis efficiency

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Clinical prediction models for progression of chronic kidney disease to end-stage kidney failure under pre-dialysis nephrology care: results from the Chronic Kidney Disease Japan Cohort Study

Warning from constricted and wrinkled internal jugular vein

Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis

Comprehensive evaluation of the significance of immunofluorescent findings on clinicopathological features in IgA nephropathy

Is medium dose of cyclosporine A effective in treatment of children with steroid-dependent nephrotic syndrome with reduction in corticosteroids dose consumption?

A review of clinical characteristics and genetic backgrounds in Alport syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page